Upregulated circulating miR-150 is associated with the risk of intrahepatic cholangiocarcinoma

Wang,Shouli; Yin,Jikai; Li,Tao; Yuan,Lijuan; Wang,Dong; He,Jiaxing; Du,Xilin; Lu,Jianguo

doi:10.3892/or.2014.3641

Upregulated circulating miR-150 is associated with the risk of intrahepatic cholangiocarcinoma

Authors:
- Shouli Wang
- Jikai Yin
- Tao Li
- Lijuan Yuan
- Dong Wang
- Jiaxing He
- Xilin Du
- Jianguo Lu
View Affiliations

Affiliations: Department of General Surgery, Tangdu Hospital of The Fourth Military Medical University, Shaanxi 710038, P.R. China, Department of General Surgery, General Hospital of Beijing Military Command, Beijing 100700, P.R. China
Published online on: December 2, 2014 https://doi.org/10.3892/or.2014.3641
Pages: 819-825

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

During the last decade, microRNAs (miRNAs) have been identified as potential biomarkers and therapeutic targets for multiple malignancies; yet, few studies exist on intrahepatic cholangiocarcinoma (ICC). In the present study, a miRNA microarray was applied to determine the significant miRNAs involved in ICC. miR-150 was found to be significantly downregulated in ICC. We further enrolled 15 ICC patients who received radical resection to test these findings in plasma. Using quantitative reverse transcription-polymerase chain reaction (qRT-PCR), we examined and quantified the expression levels of miR-150 in tumor tissues, peritumoral noncancerous tissues and blood samples of 15 ICC patients. The diagnostic value of plasma miR-150 for differentiating patients with ICC from the age- and gender-matched controls was analyzed. For plasma samples, compared with normal controls, the level of miR-150 expression was found to be upregulated (P<0.010) in ICC patients. While differentiating ICC from normal controls, receiver operator curve (ROC) analysis of plasma miR-150 revealed the area under the curve (AUC) of 0.764 (P<0.010) with sensitivity of 80.6% and specificity of 58.1%. The diagnostic value of carbohydrate antigen 19-9 (CA19-9) and the combination of miR-150 and CA19-9 were also evaluated. We found that the combination of these two markers improved the power of screening ICC. Moreover, on the basis of the plasma miR-150 level, 15 ICC patients were divided into a low or high expression group. We found that plasma miR‑150 is a potential diagnostic biomarker for ICC.

View Figures

View References

1	Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I and Molinari M: Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg. 208:134–147. 2009. View Article : Google Scholar : PubMed/NCBI
2	Patel T: Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2:102002. View Article : Google Scholar : PubMed/NCBI
3	Martin R and Jarnagin W: Intrahepatic cholangiocarcinoma. Current management. Minerva Chir. 58:469–478. 2003.PubMed/NCBI
4	de Jong MC, Nathan H, Sotiropoulos GC, et al: Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 29:3140–3145. 2011. View Article : Google Scholar : PubMed/NCBI
5	Nakagohri T, Kinoshita T, Konishi M, Takahashi S and Gotohda N: Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma. World J Surg. 32:2675–2680. 2008. View Article : Google Scholar : PubMed/NCBI
6	Morimoto Y, Tanaka Y, Ito T, et al: Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 10:432–440. 2003. View Article : Google Scholar
7	Ohtsuka M, Ito H, Kimura F, et al: Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg. 89:1525–1531. 2002. View Article : Google Scholar : PubMed/NCBI
8	Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y and Blumgart LH: Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg. 193:384–391. 2001. View Article : Google Scholar : PubMed/NCBI
9	Shen WF, Zhong W, Xu F, et al: Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. World J Gastroenterol. 15:5976–5982. 2009. View Article : Google Scholar : PubMed/NCBI
10	Li FH, Chen XQ, Luo HY, et al: Prognosis of 84 intrahepatic cholangiocarcinoma patients. Ai Zheng. 28:528–532. 2009.(In Chinese). PubMed/NCBI
11	Higashi M, Yamada N, Yokoyama S, et al: Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. Pathobiology. 79:101–106. 2012. View Article : Google Scholar : PubMed/NCBI
12	Uenishi T, Kubo S, Hirohashi K, Tanaka H, et al: Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer. Br J Cancer. 88:1894–1899. 2003. View Article : Google Scholar : PubMed/NCBI
13	Tao LY, Cai L, He XD, Liu W and Qu Q: Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Am Surg. 76:1210–1213. 2010.PubMed/NCBI
14	Rana TM: Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol. 8:23–36. 2007. View Article : Google Scholar
15	Jannot G and Simard MJ: Tumour-related microRNAs functions in Caenorhabditis elegans. Oncogene. 25:6197–6201. 2006. View Article : Google Scholar : PubMed/NCBI
16	Chen L, Yan HX, Yang W, et al: The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol. 50:358–369. 2009. View Article : Google Scholar
17	Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G and Voros D: Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 52:297–303. 2013. View Article : Google Scholar
18	Hu C, Huang F, Deng G, Nie W, Huang W and Zeng X: miR-31 promotes oncogenesis in intrahepatic cholangiocarcinoma cells via the direct suppression of RASA1. Exp Ther Med. 6:1265–1270. 2013.PubMed/NCBI
19	Zeng B, Li Z, Chen R, et al: Epigenetic regulation of miR-124 by hepatitis C virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3. FEBS Lett. 586:3271–3278. 2012. View Article : Google Scholar : PubMed/NCBI
20	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
21	Watanabe A, Tagawa H, Yamashita J, et al: The role of microRNA-150 as a tumor suppressor in malignant lymphoma. Leukemia. 25:1324–1334. 2011. View Article : Google Scholar : PubMed/NCBI
22	Farhana L, Dawson MI, Murshed F, Das JK, Rishi AK and Fontana JA: Upregulation of miR-150^* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. PLoS One. 8:e610152013. View Article : Google Scholar
23	Liu H, Zhu L, Liu B, et al: Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 316:196–203. 2012. View Article : Google Scholar
24	Meyer CG, Penn I and James L: Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation. 69:1633–1637. 2000. View Article : Google Scholar : PubMed/NCBI
25	Shimoda M, Farmer DG, Colquhoun SD, et al: Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl. 7:1023–1033. 2001. View Article : Google Scholar : PubMed/NCBI
26	Schetter AJ, Leung SY, Sohn JJ, et al: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436. 2008. View Article : Google Scholar : PubMed/NCBI
27	Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
28	Ganepola GA, Rutledge JR, Suman P, Yiengpruksawan A and Chang DH: Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. World J Gastrointest Oncol. 6:22–33. 2014. View Article : Google Scholar : PubMed/NCBI
29	Brockhausen J, Tay SS, Grzelak CA, Bertolino P, et al: miR-181a mediates TGF-β induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer. Liver Int. Feb 28–2014.(Epub ahead of print). View Article : Google Scholar
30	Yang X, Zeng Z, Hou Y, Yuan T, Gao C, Jia W, Yi X and Liu M: MicroRNA-92a as a potential biomarker in diagnosis of colorectal cancer: a systematic review and meta-analysis. PLoS One. 9:e887452014. View Article : Google Scholar : PubMed/NCBI
31	Zheng G, Xiong Y, Xu W, et al: A two-microRNA signature as a potential biomarker for early gastric cancer. Oncol Lett. 7:679–684. 2014.PubMed/NCBI
32	Zhou L, Qi X, Potashkin JA, Abdul-Karim FW and Gorodeski GI: MicroRNAs miR-186 and miR-150 down-regulate expression of the pro-apoptotic purinergic P2×7 receptor by activation of instability sites at the 3′-untranslated region of the gene that decrease steady-state levels of the transcript. J Biol Chem. 283:28274–28286. 2008. View Article : Google Scholar : PubMed/NCBI
33	Wu Q, Jin H, Yang Z, et al: MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. Biochem Biophys Res Commun. 392:340–345. 2010. View Article : Google Scholar : PubMed/NCBI
34	Yokobori T, Suzuki S, Tanaka N, et al: MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci. 104:48–54. 2013. View Article : Google Scholar
35	Srivastava SK, Bhardwaj A, Singh S, et al: MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis. 32:1832–1839. 2011. View Article : Google Scholar : PubMed/NCBI
36	Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009. View Article : Google Scholar : PubMed/NCBI
37	Chang TC, Yu D, Lee YS, et al: Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 40:43–50. 2008. View Article : Google Scholar
38	Nakanuma Y, Sasaki M, Sato Y, Ren X, Ikeda H and Harada K: Multistep carcinogenesis of perihilar cholangiocarcinoma arising in the intrahepatic large bile ducts. World J Hepatol. 1:35–42. 2009. View Article : Google Scholar : PubMed/NCBI
39	Pigati L, Yaddanapudi SC, Iyengar R, et al: Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One. 5:e135152010. View Article : Google Scholar : PubMed/NCBI